Related Experiment Videos
Gomisin A as a multi‑target therapeutic agent: Pharmacological mechanisms, pharmacokinetics and network pharmacology
Jiaqi Xu1, Sha Shi2, Chengkai Zhu2
1Department of Pharmacy, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang 310015, P.R. China.
Abstract:
Gomisin A (GA; C23H28O7) is a principal bioactive dibenzocyclooctadiene lignan derived from Schisandra chinensis (Turcz.) Baill. (Wu Wei Zi), a herb traditionally used in Chinese medicine for its adaptogenic, hepatoprotective and detoxifying properties, particularly in treating fatigue, chronic cough and liver disorders. GA exhibits multi‑target potential against a spectrum of complex diseases. The present study aimed to assess the pharmacological profile, mechanisms, pharmacokinetics (PK) and computational docking of GA, emphasizing its potential as a multi‑target agent. A comprehensive literature search was performed in the PubMed and China National Knowledge Infrastructure database platforms. All mechanistic findings were appraised and stratified by supporting evidence strength, complemented by network pharmacology screening, molecular docking and molecular dynamics (MD) assessment of representative target complexes. GA exhibits polypharmacological properties, including hepatoprotective, anticancer, cardiovascular‑modulating, neuroprotective and anti‑inflammatory/antioxidant effects, with hepatoprotection representing the most robustly supported preclinical indication. GA modulates key signaling pathways such as the PI3K/AKT/mTOR, MAPK and ErbB receptor family pathways. Network pharmacology analysis identified STAT3, EGFR and mTOR as high‑priority candidate targets. Molecular docking predicted moderate‑to‑strong binding affinity across nine hub proteins, with that of EGFR reaching ‑7.7 kcal/mol. MD simulations further supported the conformational plausibility of the GA‑EGFR, GA‑GSK3β and GA‑STAT3 complexes. PK data identified limited oral bioavailability as a key translational bottleneck. GA holds promise as a multi‑target natural product. Advancing GA toward clinical translation requires addressing PK limitations through advanced delivery systems, alongside orthogonal validation of its predicted targets and preclinical and clinical evaluation.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...